Table 3 1 L treatment patterns, duration and TT2T switch: drug class, administration route and agents
1 L treatment | Patients, n | Median duration of 1 L treatment (95% CI), monthsa | Median TT2T (95% CI), monthsa |
|---|---|---|---|
All patients | 1992 | 5.9 (5.5, 6.4) | 9.1 (8.5, 10.0) |
Class | |||
 TK/VEGF inhibitor | 1752 | 6.3 (5.8, 6.7) | 9.8 (8.9, 10.4) |
 mTOR inhibitor | 233 | 3.9 (3.4, 4.8) | 6.0 (4.6, 7.1) |
Route of administration | |||
 Oral | 1674 | 6.6 (6.0, 7.3) | 9.4 (8.6, 10.2) |
 IV | 318 | 3.4 (2.7, 3.9) | 7.3 (6.0, 9.9) |
Agent | |||
 Sunitinib (TK; oral) | 849 | 6.5 (5.9, 7.6) | 9.4 (8.5, 10.3) |
 Sorafenib (TK; oral) | 62 | 4.7 (3.3, 9.8) | 8.4 (4.8, 12.6) |
 Pazopanib (TK; oral) | 631 | 7.0 (6.0, 8.0) | 9.3 (8.2, 10.6) |
 Axitinib (TK; oral) | 56 | 12.0 (7.4, 18.8) | 14.4 (7.7, 22.3) |
 Bevacizumab (VEGF; IV) | 149 | 2.8 (1.8, 4.4) | 22.5 (11.7, NR) |
 Everolimus (mTOR; oral) | 76 | 4.0 (3.2, 6.1) | 8.0 (3.6, 11.3) |
 Temsirolimus (mTOR; IV) | 157 | 3.9 (3.0, 4.8) | 5.7 (4.3, 6.7) |